Trial reportBritish journal of clinical pharmacology2026
Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05879523 (A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
Who cites it
1 citing paper in PubMed.
- Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.British journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimThis first-in-human study assessed the safety, tolerability, pharmacokinetics (PK), effect of food on PK and pharmacodynamics of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.
methodsIn the single ascending dose part, eight subjects in each of the 5-, 15-, 50-, 75- and 100-mg (optional) cohort and 10 subjects in the 30-mg cohort were randomized in 6:2 and 8:2 ratios, respectively, to receive HRS-1893 or placebo. Participants from the 30-mg cohort then entered a food effect study where they received HRS-1893 or placebo after a high-fat meal. In the multiple ascending dose part, eight subjects in each of the 10-, 20-, 40- and 60-mg (optional) cohorts were randomized (6:2) to receive HRS-1893 or placebo twice daily for 14 days.
resultsHRS-1893 was well tolerated within the tested dose range. Following single dosing, the median (5th and 95th percentile) maximum plasma concentration of HRS-1893 ranged from 343 (241 and 436) to 1090 (990 and 1430) ng/ml and was reached within 1.0- to 2.0-h post-administration. Drug exposure increased in a less-than-dose-proportional manner with dose escalation. AUC
conclusionHRS-1893 demonstrated favourable safety and PK profiles, with potential therapeutic efficacy among healthy subjects. CLINICAL
trial registrationClinicalTrials.gov, NCT05879523.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.